Pfizer Inc (NYSE:PFE)

40.19
Delayed Data
As of Jan 22
 -0.15 / -0.37%
Today’s Change
33.97
Today|||52-Week Range
44.56
+2.58%
Year-to-Date
AstraZeneca and Merck Get an FDA Priority Review for Lynparza in Prostate Cancer
Jan 21 / MotleyFool.com - Paid Partner Content
Is Pfizer's Stock a Buy?
Jan 14 / MotleyFool.com - Paid Partner Content
2 Biotechs Battling Immune Diseases
Jan 19 / MotleyFool.com - Paid Partner Content
Biogen Buys Azheimer's and Parkinson's Drug From Pfizer
Jan 13 / MotleyFool.com - Paid Partner Content
Why Pfizer Stock Fell 10.2% in 2019
Jan 16 / MotleyFool.com - Paid Partner Content
Here's Why SpringWorks Therapeutics Climbed 69% in December
Jan 12 / MotleyFool.com - Paid Partner Content
5 Reasons 2020 Will Be a Big Year for Ionis Pharmaceuticals
Jan 16 / MotleyFool.com - Paid Partner Content
Here's Why Mylan Fell 26.6% in 2019
Jan 10 / MotleyFool.com - Paid Partner Content
New Research Shows Probiotics Can Help Prevent Parkinson's
Jan 14 / MotleyFool.com - Paid Partner Content
Why Pfizer Is My Drug Stock of Choice
Jan 10 / MotleyFool.com - Paid Partner Content
Will Theravance Biopharma Finally Break Out in 2020?
Jan 14 / MotleyFool.com - Paid Partner Content